Photo Credit: iStock.com/tumeyes
Early biologic response patterns in plaque psoriasis revealed faster remission with anti-IL-17AF and underscored the need for tailored treatment strategies.
A study published in June 2025 issue of Clinical, Cosmetic and Investigational Dermatology described how biologic therapies have reshaped the management of moderate to severe psoriasis (PsO) in Poland through the National Health Service’s B.47 program, implemented since 2013.
Researchers evaluated the effectiveness of biologic treatments during the first year of therapy in individuals with plaque PsO enrolled in the B.47 program at a single center in Poland.
They reviewed medical records of individuals diagnosed with plaque PsO who received treatment under the National Health Service’s B.47 drug program at the dermatology department which covered the data from January 1, 2013, to August 2, 2024. This analysis was based on secondary data extracted from these records. In total, 159 individuals were included in the study, accounting for 300 drug-periods (1 individual could have more than 1 treatment period with a different drug).
The results showed that 6 unique response patterns were identified within the first year of therapy. The Anti-IL-17AF treatment led to the fastest complete remission [Psoriasis Area and Severity Index-100 (PASI-100)] in 53.8 days, compared to 101.7 days for the total study group (P< 0.05). Overall, treatment outcomes did not vary between biologic-naive and non-biologic-naive individuals. However, repeated courses of anti-TNF and anti-IL-12/23 agents were linked to reduced clinical effectiveness.
Investigators concluded that strategic treatment selection played a key role in optimizing long-term outcomes for individuals with plaque PsO.
Create Post
Twitter/X Preview
Logout